BMP7 Protein (AA 315-431)

Catalog No. ABIN2666467

Product Details

Target: BMP7 (Bone Morphogenetic Protein 7 (BMP7))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 315-431

Origin: Human

Source: CHO Cells

Application: Multiplex Assay (MA)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE and HPLC analysis.

Endotoxin Level:

Less than 0.1 ng per μg of protein.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: BMP-7 induces alkaline phosphatase production on ATDC-5 cells. The ED50 = 0.02 - 0.04 μg/ml, corresponding to a specific activity of 2.5 - 5.0 x 104 unit/mg.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer containing a carrier protein such as 0.1 % BSA and store working aliquots at -20 °C to -80 °C.

Buffer: Lyophilized

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored at -20°C or -70°C.

Target Details

Target: BMP7 (Bone Morphogenetic Protein 7 (BMP7))

Alternative Name: BMP-7 (BMP7 Products)

Background: Bone morphogenetic proteins (BMPs) belong to the transforming growth factor beta (TGF-β) superfamily. BMPs play a key role in embryonic development, especially during heart, neural and cartilage development. Around 20 BMP family members have been identified and characterized. BMPs signal through serine/threonine kinase receptors, and are composed of type I and II subtypes. Four type I receptors have been identified: type IA and IB BMP receptors, type IA activin receptor, and activin receptor-like kinase I. Three type II receptors have also been recognized: type II BMP receptor and type II and IIB activin receptors. BMP-7, originally identified by its properties to induce bone formation, has been identified as an anti-fibrotic molecule, antagonizing TGF-β1. Fibrosis is associated with the emergence of fibroblasts originating from endothelial cells, suggesting an endothelial-mesenchymal transition (EndMT). TGF-β1 induces endothelial cells to undergo EndMT, whereas bone BMP-7 preserved the endothelial phenotype. BMP-7 inhibits fibrosis in the kidney, lung, liver, heart, peritonium, oral submucosa tissue, and colonic wall.

Molecular Weight: The 117 amino acid recombinant protein has a predicted molecular mass of approximately 13 kDa. Recombinant human BMP-7 is a 28.8 kDa homodimeric glycoprotein. The predicted N-terminal amino acid is Met.

Pathways: Steroid Hormone Mediated Signaling Pathway, Stem Cell Maintenance